| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1992PNAS...89.2175J |
| P356 | DOI | 10.1073/PNAS.89.6.2175 |
| P953 | full work available at URL | https://europepmc.org/articles/PMC48619 |
| https://europepmc.org/articles/PMC48619?pdf=render | ||
| P932 | PMC publication ID | 48619 |
| P698 | PubMed publication ID | 1549578 |
| P5875 | ResearchGate publication ID | 21605306 |
| P50 | author | John L. Gerin | Q1700748 |
| Nancy Haigwood | Q55205394 | ||
| David C. Montefiori | Q63302725 | ||
| P2093 | author name string | J. Zhou | |
| S. Goldstein | |||
| P. R. Johnson | |||
| L. Misher | |||
| S. Kitov | |||
| T. E. Hamm | |||
| W. T. London | |||
| P2860 | cites work | Antibody-dependent enhancement of human immunodeficiency virus type 1 infection | Q43684895 |
| Rhesus macaques inoculated with molecularly cloned simian immunodeficiency virus | Q43959433 | ||
| Simian immunodeficiency virus infection of macaques: end-stage disease is characterized by widespread distribution of proviral DNA in tissues | Q45852935 | ||
| Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine | Q45853459 | ||
| Vaccine protection against HIV-2 infection in cynomolgus monkeys | Q47573678 | ||
| An African primate lentivirus (SIVsm) closely related to HIV-2. | Q48295012 | ||
| AIDS response | Q59024333 | ||
| Anti-cell antibody in macaques | Q59098168 | ||
| Antibody-dependent enhancement of HIV infection | Q69918764 | ||
| Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques | Q27486549 | ||
| A prospective study of dengue infections in Bangkok | Q28296365 | ||
| Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 | ||
| Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus | Q33937698 | ||
| Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. | Q34214455 | ||
| Vaccine protection against simian immunodeficiency virus infection | Q34298187 | ||
| Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus | Q36299129 | ||
| Biological characterization of a simian immunodeficiency virus-like retrovirus (HTLV-IV): evidence for CD4-associated molecules required for infection. | Q36877620 | ||
| Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus | Q37375345 | ||
| Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences | Q37577555 | ||
| Antibody-dependent enhancement of viral infectivity. | Q38166689 | ||
| Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits | Q39337618 | ||
| Immune enhancement of viral infection | Q40132021 | ||
| Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. | Q40191379 | ||
| Antibody-dependent enhancement of SIV infection: further characterization and cross reactivity between macaque and sooty mangabey isolates | Q41204982 | ||
| Vaccine protection of rhesus macaques against simian immunodeficiency virus infection | Q41717021 | ||
| Expression of the C3d/EBV receptor and of other cell membrane surface markers is altered upon HIV-1 infection of myeloid, T, and B cells | Q41754196 | ||
| Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry | Q42126903 | ||
| Functional and Immunological Characterization of SIV Envelope Glycoprotein Produced in Genetically Engineered Mammalian Cells | Q42808224 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Simian immunodeficiency virus | Q1890246 |
| P304 | page(s) | 2175-2179 | |
| P577 | publication date | 1992-03-01 | |
| 1992-03-15 | |||
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge | |
| P478 | volume | 89 |
| Q34228507 | A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease |
| Q42804317 | A macaque adherent cell line that expresses human CD4 is susceptible to SIV: utility for assessing neutralizing antibody |
| Q33845764 | Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)). |
| Q33800033 | Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV |
| Q41491959 | Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys |
| Q35745815 | HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells. |
| Q36640342 | Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. |
| Q41491967 | Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells |
| Q36631918 | Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques |
| Q36630114 | Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines |
| Q36009232 | Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones |
| Q35839114 | Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. |
| Q37743813 | Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques |
| Q34150125 | Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies |
| Q24634681 | Pathogenesis of human immunodeficiency virus infection |
| Q35861490 | Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. |
| Q35621250 | Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex |
| Q40044609 | Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines. |
| Q45751941 | SIVmac vaccine studies using whole inactivated virus antigen sequentially depleted of viral proteins |
| Q30233733 | Some important issues in the planning of phase III HIV vaccine efficacy trials |
| Q36632605 | Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein |
| Q35976953 | The Trojan exosome hypothesis |
| Q44761396 | Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells |
| Q36636293 | Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge |
| Q35848231 | Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5) |
Search more.